{
  "abstract": null,
  "abstract_shown": false,
  "affiliations": [
    "Division of Pharmaceutical Quality Research V, Office of Pharmaceutical Quality Research, Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, MD 20993, USA",
    "Division of Therapeutic Performance II, Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD 20993, USA",
    "Division of Quantitative Methods and Modeling, Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD 20993, USA",
    "Division of Therapeutic Performance I, Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD 20993, USA"
  ],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 8,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Tasmin Ara Sultana"
    },
    {
      "affs": [
        1
      ],
      "name": "Manar Al-Ghabeish"
    },
    {
      "affs": [
        2
      ],
      "name": "Steven Chopski"
    },
    {
      "affs": [
        2
      ],
      "name": "Ross Walenga"
    },
    {
      "affs": [
        0
      ],
      "name": "Diaa Shakleya"
    },
    {
      "affs": [
        3
      ],
      "name": "Bryan Newman"
    },
    {
      "affs": [
        0
      ],
      "name": "Muhammad Ashraf"
    },
    {
      "affs": [
        0
      ],
      "name": "Ahmed Zidan",
      "orcid": "0000-0002-5830-4213"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/dp8hm62ggawdf.bib",
  "cited_by": 0,
  "doi": "10.1007/s11095-026-04153-w",
  "fulltext_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC13735040/",
  "id": "dp8hm62ggawdf",
  "issns": [
    "0724-8741",
    "1573-904X"
  ],
  "landing_url": "https://doi.org/10.1007/s11095-026-04153-w",
  "language": "en",
  "licence": "unknown",
  "licence_label": "Licence not stated",
  "licence_source": "unknown",
  "licence_url": null,
  "metadata_licence": null,
  "native_subjects": [
    [
      "heading",
      "Article"
    ],
    [
      "openalex",
      "3003|Advanced Drug Delivery Systems"
    ]
  ],
  "openalex": "W7171658407",
  "pdf_url": null,
  "pmcid": "PMC13735040",
  "pmid": "42527804",
  "published": "2026-07-30",
  "publisher": null,
  "ris": "https://research.draconitic.com/paper/dp8hm62ggawdf.ris",
  "sources": [
    {
      "first_seen": "2026-11-09T12:20:49Z",
      "native_id": "PMC13735040",
      "source": "pmc",
      "url": "https://doi.org/10.1007/s11095-026-04153-w"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:3003|Advanced Drug Delivery Systems",
      "subfield": "pharmacology-toxicology"
    }
  ],
  "title": "Development of an In Vitro Permeation Test Framework For Naloxone Hydrochloride Intranasal Spray: Establishing IVIVR for Bioequivalence Assessment",
  "title_text": "Development of an In Vitro Permeation Test Framework For Naloxone Hydrochloride Intranasal Spray: Establishing IVIVR for Bioequivalence Assessment",
  "type": "peer-reviewed",
  "updated_at": "2026-11-09T12:20:49Z",
  "url": "https://research.draconitic.com/paper/dp8hm62ggawdf",
  "venue": "Pharmaceutical research",
  "versions": []
}